Journal
JOURNAL OF IMMUNOLOGY
Volume 171, Issue 6, Pages 3136-3141Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.171.6.3136
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL-30542] Funding Source: Medline
- NIGMS NIH HHS [GM-42686] Funding Source: Medline
Ask authors/readers for more resources
Transgenic mice that over-express B cell leukemia/lymphomas (Bel)-2 in myeloid cells under control of the human MRP8 promoter (hMRP8-Bcl-2) or in T lymphocytes under the Emu promoter (Emu-Bcl-2) were compared with C57BL/6 control mice following cecal ligation and puncture (CLP). There was a significant difference in outcome between the hMRP8-Bcl-2 and control mice with 100% survival in the hMRP8-Bcl-2 mice vs 25% survival in the control mice. In separate experiments there was a significant difference between Emu-Bcl-2 and control mice with 87.5 and 22.2% survival, respectively. Adoptive transfer of CD11b-positive bone marrow cells from hMRP8-Bcl-2 or C57BL/6 mice to C57BL/6 mice subjected to CLP resulted in 100 and 0% survival, respectively. Adoptive transfer of CD11b-positive cells from either hMRP8-Bcl-2 or C57BL/6 mice to Rag-1(-/-) mice (no mature T or B cells) subjected to CLP resulted in survival of 87.5 and 12.5%, respectively. The hMRP8-Bcl-2 mice had significantly more neutrophils and fewer bacteria in the peritoneum compared with C57BL/6 mice 24 h after CLP. These experiments show that Bcl-2 over-expression is protective in CLP and that protection is independent of lymphocytes. We propose that overexpression of Bcl-2 in T cells or myeloid cells induce release of a molecule(s) that protects against death following CLP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available